Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock Holdings Decreased by Millennium Management LLC

Millennium Management LLC reduced its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 87.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 30,470 shares of the specialty pharmaceutical company's stock after selling 222,273 shares during the period. Millennium Management LLC owned 0.06% of Supernus Pharmaceuticals worth $1,102,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Smartleaf Asset Management LLC lifted its stake in shares of Supernus Pharmaceuticals by 219.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock valued at $47,000 after buying an additional 870 shares during the period. Mark Sheptoff Financial Planning LLC acquired a new position in Supernus Pharmaceuticals in the 4th quarter valued at $52,000. Headlands Technologies LLC lifted its stake in shares of Supernus Pharmaceuticals by 203.0% during the 4th quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company's stock worth $55,000 after purchasing an additional 1,015 shares during the period. Newbridge Financial Services Group Inc. purchased a new position in shares of Supernus Pharmaceuticals during the 4th quarter worth $72,000. Finally, Venturi Wealth Management LLC acquired a new stake in Supernus Pharmaceuticals in the 4th quarter worth about $92,000.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ SUPN traded up $0.81 during midday trading on Friday, reaching $33.15. 354,750 shares of the company's stock were exchanged, compared to its average volume of 480,715. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $40.28. The business's fifty day moving average price is $31.92 and its two-hundred day moving average price is $34.49. The stock has a market capitalization of $1.86 billion, a PE ratio of 30.98 and a beta of 0.74.

Analyst Upgrades and Downgrades

Several brokerages recently commented on SUPN. Wall Street Zen raised shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, May 16th. Cantor Fitzgerald reissued a "neutral" rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.